Non‑Small Cell Lung Cancer (NSCLC): Overview
NSCLC accounts for approximately 85 % of all lung cancers.
This Medscape overview summarises the epidemiology, risk factors, genetics, and clinical presentation of non‑small cell lung cancer (NSCLC), the most common form of lung cancer comprising adenocarcinoma, squamous cell carcinoma and large‑cell carcinoma.
NSCLC is the leading cause of cancer‑related deaths worldwide, making early detection and effective, targeted therapies a priority for clinicians and researchers.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT